Therapeutic Proteins Market to 2017 by GBIResearch

VIEWS: 174 PAGES: 142

More Info
									         Therapeutic Proteins Market to 2017 - High Demand for
              Monoclonal Antibodies will Drive the Market
 Reference Code: GBIHC080MR                                                                                      Publication Date: September 2011


                                     Moderate Growth Rate and Increasing Competition for the Therapeutic Proteins Market

The global therapeutic               The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies
proteins market was worth            considered to be the highest revenue generating market in 2010. This will also be the leading
$93 billion in 2010 and is           market in the coming years. The global therapeutic proteins market was worth $93 billion in 2010
forecast to grow to $141.5           and is forecast to grow to $141.5 billion by 2017, which represents a growth rate of 6.2% between
billion by 2017 at a CAGR            2010 and 2017. With the advancements in the biogenerics and gene therapy markets, the
of 6.2%                              therapeutic proteins market is expected to show a moderate growth rate in the coming years. On
                                     the other hand, the introduction of new oral therapeutic proteins will increase the patient pool due to
                                     better drug compliance. Even though the competition from gene therapy and the biogenerics
                                     market will influence the market, the market is still very attractive for the pharmaceutical
                                     companies.

                                       Therapeutic Proteins Market, Global, Revenue Forecasts ($bn), 2002-2017

                                                            160

                                                                                         CAGR (2010-2017) : 6.2%
                                                            140


                                                            120
                                                                  CAGR (2002-2010) : 16.4%
                                                            100
                                            Revenue ($bn)




                                                            80


                                                            60


                                                            40


                                                            20


                                                             0
                                                                        2002                        2010                          2017


                                       Source: GBI Research, Oxford Journal, CDC




Therapeutic Proteins Market to 2017 - High Demand for                                                               GBIHC080MR / Published SEP 2011
Monoclonal Antibodies will Drive the Market
                                                                                                                                                 Page 1
                                                                                  © GBI Research. This is a licensed product and is not to be photocopied
                                     Moderate Pipeline and the Entry of New Players will Intensify the Competition
                                     The therapeutic proteins market has a moderate pipeline base, supporting growth in the market
                                     and thereby attracting the pharmaceutical and biotechnological companies. Major pharmaceutical
                                     companies such as Amgen, Roche and Johnson & Johnson have active therapeutic proteins
                                     pipelines. One of the major activities in the market at present is the development of generic
                                     versions of off-patent drugs. The entry of these generic versions will boost the therapeutic proteins
                                     market and thereby bring about further growth in the therapeutic proteins market in the coming
                                     years. The rapid entry of new players is set to intensify competition in this market.
                                     The Therapeutic Proteins Market is Concentrated, with the Top Three Companies Having
                                     Significant Market Shares
                                     The global therapeutic proteins market is dominated by three major pharmaceutical companies,
                                     which account for a significant percentage of the market. The top company is Roche, followed by
                                     Amgen and Novo Nordisk. Although three top companies dominate the market, there are also a
                                     number of small pharmaceutical companies in the market, making it a strong market in terms of
                                     competition. However, the development of blockbuster drugs has made these three companies the
                                     dominant players in the market. Roche markets Rituxan, Epogin, Herceptin, Pegasys, and
                                     Nutropin, and has total revenues of $22.4 billion; Amgen markets Aranesp, Neupogen, and
                                     Neulasta, and has total revenues of $19.7 billion; Novo Nordisk, through its drugs Novolin and
                                     Novolog, has total revenues of $8.6 billion in the therapeutic proteins market.

                                       Therapeutic Proteins Market, Global, Market Share Analysis by Company (%), 2010


                                                                                                            Roche
                                                                                                             27%




                                                            Others                                               Merck & Co
                                                             61%                                                    6%

                                                                                                             Eli Lilly
                                                                                                               6%


                                       Source: GBI Research, Companies Annual report




Therapeutic Proteins Market to 2017 - High Demand for                                                           GBIHC080MR / Published SEP 2011
Monoclonal Antibodies will Drive the Market
                                                                                                                                             Page 2
                                                                              © GBI Research. This is a licensed product and is not to be photocopied
                                     1         Table of Contents
                                     1   Table of Contents ........................................................................................................................ 3
                                         1.1    List of Tables..................................................................................................................... 6
                                         1.2    List of Figures ................................................................................................................... 9
                                     2   Therapeutic Proteins Market: Introduction ................................................................................. 11
                                         2.1    GBI Research Report Guidance ..................................................................................... 11
                                     3   Therapeutic Proteins Market: Market Overview ......................................................................... 12
                                         3.1    Introduction ..................................................................................................................... 12
                                            3.1.1    Drivers and Barriers................................................................................................. 12
                                     4   Therapeutic Proteins Market: Market Characterization.............................................................. 14
                                         4.1    Market Size ..................................................................................................................... 14
                                     5   Therapeutic Proteins Market: Geographical Landscape ............................................................ 15
                                         5.1    Revenue Analysis by Geography .................................................................................... 15
                                         5.2    The US ............................................................................................................................ 15
                                            5.2.1    Market Size.............................................................................................................. 15
                                         5.3    Europe ............................................................................................................................ 16
                                            5.3.1    Market Size.............................................................................................................. 16
                                         5.4    ROW (Rest of the World) ................................................................................................ 17
                                            5.4.1    Market Size.............................................................................................................. 17
                                     6   Therapeutic Proteins Market: Therapeutic Landscape .............................................................. 18
                                         6.1    Introduction ..................................................................................................................... 18
                                         6.2    Erythropoietins Market .................................................................................................... 18
                                            6.2.1    Introduction .............................................................................................................. 18
                                            6.2.2    Market Size.............................................................................................................. 19
                                            6.2.3    Annual Cost of Treatment for Major Therapies ........................................................ 23
                                         6.3    Blood Factors Market ...................................................................................................... 24
                                            6.3.1    Introduction .............................................................................................................. 24
                                            6.3.2    Market Size.............................................................................................................. 25
                                            6.3.3    Annual Cost of Treatment for Major Therapies ........................................................ 29
                                         6.4    Interferons Market ........................................................................................................... 30
                                            6.4.1    Introduction .............................................................................................................. 30
                                            6.4.2    Market Size.............................................................................................................. 31
                                            6.4.3    Annual Cost of Treatment for Major Therapies ........................................................ 35
                                         6.5    Monoclonal Antibodies Market ........................................................................................ 36
                                            6.5.1    Introduction .............................................................................................................. 36
                                            6.5.2    Market Size.............................................................................................................. 37
                                            6.5.3    Annual Cost of Treatment for Major Therapies ........................................................ 41
                                         6.6    Growth Hormones Market ............................................................................................... 42
                                            6.6.1    Introduction .............................................................................................................. 42
                                            6.6.2    Market Size.............................................................................................................. 43
                                            6.6.3    Annual Cost of Treatment for Major Therapies ........................................................ 47
                                         6.7    Insulin Market.................................................................................................................. 48
                                            6.7.1    Introduction .............................................................................................................. 48
                                            6.7.2    Market Size.............................................................................................................. 49
                                            6.7.3    Annual Cost of Treatment for Major Therapies ........................................................ 53
                                         6.8    Colony Stimulating Factors Market ................................................................................. 54
                                            6.8.1    Introduction .............................................................................................................. 54
                                            6.8.2    Market Size.............................................................................................................. 55
                                            6.8.3    Annual Cost of Treatment for Major Therapies ........................................................ 59
                                     7   Therapeutic Proteins Market: Pipeline Analysis......................................................................... 60
                                         7.1    Introduction ..................................................................................................................... 60
                                         7.2    Profiles of Promising Proteins in the Therapeutic Proteins Market ................................. 60
                                            7.2.1    rhGAD65 (Diamyd) .................................................................................................. 60
                                            7.2.2    DiaPep277 ............................................................................................................... 60


Therapeutic Proteins Market to 2017 - High Demand for                                                                                GBIHC080MR / Published SEP 2011
Monoclonal Antibodies will Drive the Market
                                                                                                                                                                            Page 3
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                           7.2.3   Otelixizumab ............................................................................................................ 61
                                           7.2.4   Oral-Lyn ................................................................................................................... 62
                                           7.2.5   NecLip-pdFVIII......................................................................................................... 62
                                           7.2.6   OBI-1 ....................................................................................................................... 63
                                           7.2.7   NN7008 ................................................................................................................... 64
                                           7.2.8   Long Acting rFactor VIII ........................................................................................... 65
                                           7.2.9   Human-cl rhFVIII ..................................................................................................... 66
                                           7.2.10 Abthrax (raxibacumab) ............................................................................................ 67
                                           7.2.11 Simponi (golimumab)............................................................................................... 68
                                     8 Therapeutic Proteins Market: Competitive Landscape .............................................................. 69
                                        8.1    Evolving Competitive Landscape .................................................................................... 69
                                        8.2    Market Share Analysis .................................................................................................... 69
                                           8.2.1   Major Companies .................................................................................................... 69
                                        8.3    Competitive Profiling ....................................................................................................... 70
                                           8.3.1   Pfizer ....................................................................................................................... 70
                                           8.3.2   Johnson & Johnson ................................................................................................. 79
                                           8.3.3   Hoffmann-La Roche Ltd. ......................................................................................... 83
                                           8.3.4   Merck & Co., Inc ...................................................................................................... 87
                                           8.3.5   Eli Lilly and Company .............................................................................................. 96
                                           8.3.6   Abbott Laboratories ............................................................................................... 104
                                           8.3.7   Sanofi .................................................................................................................... 108
                                           8.3.8   Novo Nordisk ......................................................................................................... 114
                                           8.3.9   Amgen ................................................................................................................... 117
                                           8.3.10 Biogen ................................................................................................................... 119
                                     9 Therapeutic Proteins Market – Strategic Consolidations ......................................................... 121
                                        9.1    Therapeutic Proteins Market – Mergers and Acquisitions ............................................. 121
                                           9.1.1   M&A Deals by Year ............................................................................................... 121
                                           9.1.2   M&A Deals by Value.............................................................................................. 122
                                           9.1.3   M&A Deals by Drug Class ..................................................................................... 122
                                           9.1.4   M&A Deals by Geography ..................................................................................... 123
                                           9.1.5   Major M&A Deals................................................................................................... 124
                                        9.2    Global Therapeutic Proteins Market – Licensing Deals ................................................ 126
                                           9.2.1   Licensing Deals by Year ........................................................................................ 126
                                           9.2.2   Licensing Deals by Value ...................................................................................... 127
                                           9.2.3   Licensing Deals by Drug Class .............................................................................. 128
                                           9.2.4   Licensing Deals by Geography .............................................................................. 129
                                           9.2.5   Major Licensing Deals ........................................................................................... 129
                                        9.3    Global Therapeutic Proteins Market – Co-Development Deals ..................................... 132
                                           9.3.1   Co-Development Deals by Year ............................................................................ 132
                                           9.3.2   Co-Development Deals by Value........................................................................... 133
                                           9.3.3   Co-Development Deals by Drug Class .................................................................. 133
                                           9.3.4   Co-Development Deals by Geography .................................................................. 134
                                           9.3.5   Major Co-Development Deals................................................................................ 134
                                     10 Global Therapeutic Proteins Market: Appendix ....................................................................... 137
                                        10.1 Market Definitions ......................................................................................................... 137
                                        10.2 Abbreviations ................................................................................................................ 137
                                        10.3 Research Methodology ................................................................................................. 137
                                           10.3.1 Coverage ............................................................................................................... 137
                                           10.3.2 Secondary Research ............................................................................................. 138
                                           10.3.3 Primary Research .................................................................................................. 138
                                        10.4 Therapeutic Landscape ................................................................................................ 139
                                           10.4.2 Market Size by Geography .................................................................................... 140
                                        10.5 Geographical Landscape .............................................................................................. 141
                                        10.6 Pipeline Analysis ........................................................................................................... 141
                                        10.7 Competitive Landscape ................................................................................................ 141

Therapeutic Proteins Market to 2017 - High Demand for                                                                               GBIHC080MR / Published SEP 2011
Monoclonal Antibodies will Drive the Market
                                                                                                                                                                          Page 4
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                           10.7.1 Expert Panel Validation ......................................................................................... 141
                                        10.8 Contact Us .................................................................................................................... 141
                                        10.9 Disclaimer ..................................................................................................................... 141
                                        10.10 Sources ......................................................................................................................... 142




Therapeutic Proteins Market to 2017 - High Demand for                                                                              GBIHC080MR / Published SEP 2011
Monoclonal Antibodies will Drive the Market
                                                                                                                                                                         Page 5
                                                                                     © GBI Research. This is a licensed product and is not to be photocopied
                                     1.1     List of Tables
                                     Table 1:    Therapeutic Proteins Market, Global Market, Historical Revenue ($bn), 2002-2010..... 14
                                     Table 2:    Therapeutic Proteins Market, Global Market, Revenue Forecasts ($bn), 2010-2017.... 14
                                     Table 3:    Therapeutic Proteins Market, the US, Historical Revenue ($bn), 2002-2010 ................. 15
                                     Table 4:    Therapeutic Proteins Market, the US, Revenue Forecasts ($bn), 2010-2017 ................ 15
                                     Table 5:    Therapeutic Proteins Market, Europe, Historical Revenue ($bn), 2002-2010 ................ 16
                                     Table 6:    Therapeutic Proteins Market, Europe, Revenue Forecasts ($bn), 2010-2017 ............... 16
                                     Table 7:    Therapeutic Proteins Market, ROW, Historical Revenue ($bn), 2002-2010 ................... 17
                                     Table 8:    Therapeutic Proteins Market, ROW, Revenue Forecasts ($bn), 2010-2017 .................. 17
                                     Table 9:    Erythropoietin Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 ...... 19
                                     Table 10:   Erythropoietin Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 ..... 19
                                     Table 11:   Erythropoietin Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 ..... 20
                                     Table 12:   Erythropoietin Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 .... 20
                                     Table 13:   Erythropoietin Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010..... 21
                                     Table 14:   Erythropoietin Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 ... 21
                                     Table 15:   Erythropoietin Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 ........ 22
                                     Table 16:   Erythropoietin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 ....... 22
                                     Table 17:   Blood Factors Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 ...... 25
                                     Table 18:   Blood Factors Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 ..... 25
                                     Table 19:   Blood Factors Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 ..... 26
                                     Table 20:   Blood Factors Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 .... 26
                                     Table 21:   Blood Factors Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010..... 27
                                     Table 22:   Blood Factors Market Size Forecast, Europe, Revenue Forecasts ($bn), 2010-2017 .. 27
                                     Table 23:   Blood Factors Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 ........ 28
                                     Table 24:   Blood Factors Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 ....... 28
                                     Table 25:   Interferons Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 ............ 31
                                     Table 26:   Interferons Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 ........... 31
                                     Table 27:   Interferons Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 ........... 32
                                     Table 28:   Interferons Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 .......... 32
                                     Table 29:   Interferons Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010........... 33
                                     Table 30:   Interferons Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 ......... 33
                                     Table 31:   Interferons Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 ............. 34
                                     Table 32:   Interferons Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 ............ 34
                                     Table 33:   Monoclonal Antibody Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010
                                                 ....................................................................................................................................... 37
                                     Table 34:   Monoclonal Antibody Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-
                                                 2017 ............................................................................................................................... 37
                                     Table 35:   Monoclonal Antibody Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010
                                                 ....................................................................................................................................... 38
                                     Table 36:   Monoclonal Antibody Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-
                                                 2017 ............................................................................................................................... 38
                                     Table 37:   Monoclonal Antibody Therapeutics Market, Europe, Historical Revenue ($bn), 2002-
                                                 2010 ............................................................................................................................... 39
                                     Table 38:   Monoclonal Antibody Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-
                                                 2017 ............................................................................................................................... 39
                                     Table 39:   Monoclonal Antibody Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010
                                                 ....................................................................................................................................... 40
                                     Table 40:   Monoclonal Antibody Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017
                                                 ....................................................................................................................................... 40
                                     Table 41:   Growth Hormones Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010
                                                 ....................................................................................................................................... 43
                                     Table 42:   Growth Hormones Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
                                                 ....................................................................................................................................... 43
                                     Table 43:   Growth Hormones Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010
                                                 ....................................................................................................................................... 44
                                     Table 44:   Growth Hormones Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017
                                                 ....................................................................................................................................... 44
                                     Table 45:   Growth Hormones Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010
                                                 ....................................................................................................................................... 45
                                     Table 46:   Growth Hormones Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017
                                                 ....................................................................................................................................... 45
                                     Table 47:   Growth Hormones Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 46

Therapeutic Proteins Market to 2017 - High Demand for                                                                                  GBIHC080MR / Published SEP 2011
Monoclonal Antibodies will Drive the Market
                                                                                                                                                                                Page 6
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                     Table 48:   Growth Hormones Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 46
                                     Table 49:   Insulin Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 .................. 49
                                     Table 50:   Insulin Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 ................. 49
                                     Table 51:   Insulin Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 .................. 50
                                     Table 52:   Insulin Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 ................. 50
                                     Table 53:   Insulin Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 ................. 51
                                     Table 54:   Insulin Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 ................ 51
                                     Table 55:   Insulin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2010 ................... 52
                                     Table 56:   Insulin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 ................... 52
                                     Table 57:   Colony Stimulating Factor Therapeutics Market, Global, Historical Revenue ($bn), 2002-
                                                 2010 ............................................................................................................................... 55
                                     Table 58:   Colony Stimulating Factor Therapeutics Market, Global, Revenue Forecasts ($bn),
                                                 2010-2017 ...................................................................................................................... 55
                                     Table 59:   Colony Stimulating Factor Therapeutics Market, the US, Historical Revenue ($bn), 2002-
                                                 2010 ............................................................................................................................... 56
                                     Table 60:   Colony Stimulating Factor Therapeutics Market, the US, Revenue Forecasts ($bn),
                                                 2010-2017 ...................................................................................................................... 56
                                     Table 61:   Colony Stimulating Factor Therapeutics Market, Europe, Historical Revenue ($bn),
                                                 2002-2010 ...................................................................................................................... 57
                                     Table 62:   Colony Stimulating Factor Therapeutics Market, Europe, Revenue Forecasts ($bn),
                                                 2010-2017 ...................................................................................................................... 57
                                     Table 63:   Colony Stimulating Factor Therapeutics Market, ROW, Historical Revenue ($bn), 2002-
                                                 2010 ............................................................................................................................... 58
                                     Table 64:   Colony Stimulating Factor Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-
                                                 2017 ............................................................................................................................... 58
                                     Table 65:   Therapeutic Proteins Market, Global, Pfizer, Sales of Major Marketed Products, 2011 . 70
                                     Table 66:   Therapeutic Proteins Market, Global, Pfizer, Pipeline, Phase I Molecules, 2011 ........... 71
                                     Table 67:   Therapeutic Proteins Market, Global, Pfizer, Pipeline, Phase II Molecules, 2011 .......... 74
                                     Table 68:   Therapeutic Proteins Market, Global, Pfizer, Pipeline, Phase III Molecules, 2011 ......... 77
                                     Table 69:   Therapeutic Proteins Market, Global, Johnson & Johnson, Sales of Marketed Products,
                                                 2010 ............................................................................................................................... 79
                                     Table 70:   Therapeutic Proteins Market, Global, Johnson & Johnson, Pipeline, Phase I Molecules,
                                                 2011 ............................................................................................................................... 80
                                     Table 71:   Therapeutic Proteins Market, Global, Johnson & Johnson, Pipeline, Phase II Molecules,
                                                 2011 ............................................................................................................................... 81
                                     Table 72:   Therapeutic Proteins Market, Global, Johnson & Johnson, Pipeline, Phase III Molecules,
                                                 2011 ............................................................................................................................... 82
                                     Table 73:   Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, Sales of Marketed
                                                 Products, 2010 ............................................................................................................... 83
                                     Table 74:   Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, Pipeline, Phase I
                                                 Molecules, 2011 ............................................................................................................. 84
                                     Table 75:   Therapeutic Pro
								
To top